Tertiary-butyl acetate (TBAC) was tested for subchronic toxicity in rats and mice and reproductive toxicity in rats at inhalation concentrations of 0, 100, 400 or 1600 ppm. An oral maternal toxicity study was conducted in rats at dose levels of 0, 400, 800, 1000 and 1600 mg kg À1 d
Introduction
Volatile organic compounds (VOCs) are regulated as tropospheric ozone precursors in the U.S. and Canada. Those volatile organic compounds that have negligible photochemical reactivity 1 can be excluded from the regulatory definition of a VOC and exempted from VOC emission and product content limits. Thus, substitution of VOC-exempt compounds for photochemically reactive organic (i.e., VOC) solvents has become an important VOC-compliance strategy. Substitution of exempt compounds for VOCs offers a number of advantages over other low-VOC technologies, including lower energy consumption, less retraining of workers, and lower costs. From an environmental perspective, it is estimated that an average of 93% reduction in ozone formation from the same emissions can be achieved by replacing a VOC with a VOC-exempt compound.
2
In 1997, tertiary-butyl acetate (TBAC) was developed as a negligibly reactive solvent, useful in the formulation of coatings, sealants and adhesives, inks, and industrial cleaners. A petition was submitted to the U.S. Environmental Protection Agency (U.S.EPA) to have TBAC added to the list of exempt compounds based on its Maximum Incremental Reactivity (MIR) of 0.17 g/g ozone. In 2004, the U.S.EPA promulgated a final rule revising the definition of VOCs for the purposes of Federal regulations related to attaining the National Ambient Air Quality Standards for ozone under Title 1 of the Clean Air Act to exclude TBAC (Code of Federal Regulations, title 40, Sec. 51.100).
Since its VOC exemption, increased TBAC use has resulted in an estimated reduction of 400+ million pounds of ground-level ozone being formed from solvent emissions in the U.S. and Canada.
3 Additionally, TBAC does not form respirable particulates, 4 does not deplete stratospheric ozone or contribute to global warming, 5 and does not persist in the environment or bio-accumulate. 6 It is also not a listed carcinogen or reproductive toxicant by the U.S.EPA. However, at the time of the exemption, developmental, subchronic and chronic data on TBAC did not exist. One outcome of the U.S.EPA VOC exemption process was for the manufacturer to conduct 13-week subchronic TBAC inhalation toxicity studies with mice and rats and a reproductive screening study with rats. Protocols were developed to meet these requirements that were enhanced with additional endpoints beyond those included in the U.S. EPA Test Guidelines 870.3465, 870.3650, 870.6200, and 870.7800. At the time of these regulatory activities, a paper was published describing a TBAC developmental toxicity study using the oral route of exposure (Yang et al., 2007) . Since the toxicity of TBAC, following repeated oral exposures, was poorly understood, a study was designed to investigate maternal toxicity of TBAC following oral administration as conducted in Yang et al. (2007) and to include a limit dose (1000 mg kg À1 d À1 ) as required in U.S.EPA test guidelines.
A previous publication (Cruzan and Kirkpatrick, 2006 ) described many of the previously conducted studies with TBAC, including metabolism, acute toxicity and 14-day repeated exposure inhalation toxicity studies. Budroe et al. (2004; Corrigendum, 2006) focused on acute toxicity values and a cancer risk assessment based on genotoxicity and cancer bioassays with a metabolite of TBAC, tertiary butyl alcohol (TBA). The lack of repeated-exposure studies for TBAC was noted in the Budroe et al. (2004) publication. The purpose of this publication is to report the findings of the new TBAC toxicity studies.
Methods

Good laboratory practices
All studies were conducted according to U.S. EPA Good Laboratory Practices and OECD Guidelines C (97) 186/Final.
Test material
Tertiary-butyl acetate (CAS #540-88-5) was provided by Lyondell Chemical Company (Houston, TX, USA) and all batches used were >98.7% pure.
Animals and husbandry
Mice (Crl:CD1(IGR)) and rats (Crl:CD(SD)) were received in good health from Charles River Laboratories, Inc. (Raleigh, NC, USA). Animals were maintained in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council, 1996) and the animal care programs and facilities of the performing laboratory are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International, Frederick, MD, USA). Animals were acclimatized to the laboratory for at least 14 days and housed in stainless steel cages suspended above cage board or in plastic maternity boxes with ground corncob bedding (Bed-O'Cobs Ò ; The Andersons, Industrial Products Division, Maumee, OH, USA). Animals were provided with LLC, Certified Rodent LabDiet Ò 5002 (PMI Nutrition International, Shoreview, MN, USA) and reverse osmosis-treated (on-site) drinking water (delivered by an automatic watering system) ad libitum except during the inhalation exposure. Animals were housed in rooms with a controlled average temperature of 21 ± 3°C and an average relative humidity of 50 ± 20%. Fluorescent lighting provided for a 12 h light/dark photoperiod.
TBAC vapor generation
TBAC was generated for inhalation exposure as a vapor using a glass-bead, column-type vaporization system. The test article was metered to the column, heated to an appropriate temperature to produce vaporization of the test article and the concentrated vapors were piped to the chamber inlet where the concentration was reduced by mixing with chamber ventilation air. The control animals were exposed to clean filtered air. Temperature, relative humidity, chamber ventilation rate and negative pressure within the exposure chambers were recorded at regular intervals throughout the 6-hour exposure period (0800-1400 h daily). Actual exposure concentrations were determined by standard gas chromatographic (GC) methods with sample collection from the approximate animal-breathing zone of the inhalation exposure chambers.
TBAC dosing solutions for maternal oral gavage toxicity study
The TBAC dosing solutions were formulated daily with a corn oil vehicle and stirred continuously throughout preparation, sampling and dose administration. All dosing solutions were used within 1-3 h of preparation.
Rat subchronic study
Rats (7 weeks of age) were randomized into groups based on body weight stratification in a block design to one of 4 groups containing a total of 10 animals/sex/group. The rats were exposed to 0, 100, 400, or 1600 ppm (0, 473, 1892, 7568 mg m À3 ) TBAC for 6 h d
À1
, 7 days per week for 13 weeks. Clinical examinations were performed prior to and approximately 1 h following the daily inhalation exposure. During exposure, animals that were visible within the exposure chamber were observed at approximately the mid-point of the exposure period. The animals were then further randomized into 4 study replicates for modified functional observational battery (FOB) and locomotor activity assessments consistent with U.S.EPA recommendations (U.S.EPA, 1998). FOB assessments (Table 1) were recorded for all animals prior to the initiation of TBAC exposure and before the daily exposure period during weeks 3 and 12. Unlike the clinical examinations, the modified FOB observations were conducted by a single observer trained in the conduct of FOB's using positive controls, without knowledge of treatment group. Locomotor activity was assessed following the completion of the FOB using a photobeam activity system (San Diego Instruments, Inc., San Diego, CA, USA) as described in Chengelis et al. (2008) and Dmitrienko et al. (2007) . Locomotor data was collected in 5-min epochs and the test session duration was 60 min. Total and ambulatory motor activity was compiled as four 15-min subsessions for statistical analysis. Total motor activity was defined as a combination of fine motor skills (repeated interruption of a single photobeam) and ambulatory motor activity (interruption of 2 or more consecutive photobeams). Individual body weights and feed consumption were recorded weekly starting one week prior to study initiation and continued to study termination. Ophthalmic examinations were performed on all animals prior to the initiation of TBAC exposure and during study week 12. Individual body weights and feed consumption were recorded weekly. Final fasted body weights were recorded prior to scheduled necropsy. Blood and urine samples for clinical pathology evaluations (hematology, serum chemistry and urinalysis) were collected from all animals during study weeks 4 and 13 (scheduled necropsy). Blood parameters evaluated are listed in the U.S.EPA OPPTS Health Effects Test Guideline 870.3465 (90-Day Inhalation Toxicity). All animals were fasted overnight when urine was collected in metabolism cages.
A necropsy was performed on all animals following isoflurane anesthesia and exsanguination and included examination of the external surface, all orifices, and the cranial, thoracic, abdominal and pelvic cavities, including viscera. Tissues and organs were collected and placed in 10% neutral-buffered formalin as listed in the U.S.EPA Test Guideline 870.3465. The adrenal glands, brain, epididymides, kidneys, liver, lungs, ovaries with oviducts, spleen, testes, thymus, thyroid with parathyroids and uterus were weighed from all animals at the scheduled necropsy. After routine preparation for histopathological examination, tissues were examined microscopically. In order to evaluate specific histological features in greater detail than what was involved in the initial histological examination, selected immune system organs were examined a second time. To facilitate this examination an extended microscopic examination of the spleen, thymus, Peyer's patches, bone marrow and mandibular, mesenteric, bronchial and mediastinal lymph nodes was conducted (Table 2) . Two longitudinal sections of the kidney from each male rat were subjected to a 2 u-globulin immunohistochemical evaluation. In addition, frozen kidney tissue from each male rat was analyzed for a 2 u-globulin by ELISA (Borghoff et al., 2009 ).
Mouse subchronic study
Mice (7 weeks of age) were randomized into groups based on body weight stratification in a block design of 4 groups containing a 30 animals/sex/group. The mice were exposed to 0, 100, 400, or 1600 ppm TBAC for 6 h/d, 7 d/week for 13 weeks. Clinical examinations were performed prior to and within 1 hour following the daily inhalation exposure. These clinical examinations were performed on 30 animals/sex/group during approximately the first 4 weeks of the study and on 10 animals/sex/group for the remainder of the study. During exposure, animals that were visible within the exposure chamber were observed at approximately the midpoint of the exposure period. The during-exposure observations were difficult to confirm due to their borderline and subjective nature. When the during-exposure observations were noted in only in sporadic, inconsistent, isolated incidences during the 13-week period of daily exposure and observation, they were not considered test-article related or toxicologically significant. FOB observations (Table 1) were conducted on study days 62 (10 males/group) and 63 (10 females/group) after the end of exposure. Observations found during the post-exposure clinical examinations were considered more reliable that the during-exposure findings due to the difficult and limitations of observing animals within the exposure chambers. Ophthalmic examinations were performed on all animals prior to the initiation of TBAC exposure and during study week 12. After 10 weeks of inhalation exposure, oestrus cyclicity was determined for 3 weeks in 10 females per group. Individual body weights and feed consumption were recorded weekly. Final fasted body weights were recorded prior to scheduled necropsy.
Terminal blood samples for clinical pathology (hematology and serum chemistry) were collected from 10 animals/sex/group during study week 5. Terminal blood samples were collected from all surviving animals prior to the scheduled necropsy on study week 13 for similar determinations. Blood parameters evaluated are listed in the U.S.EPA OPPTS Health Effects Test Guideline 870.3465. The week 13 necropsy was performed on all animals following isoflurane anesthesia and exsanguination and included examination of the external surface, all orifices, and the cranial, thoracic, abdominal and pelvic cavities, including viscera. Tissues and organs were collected and placed in 10% neutral-buffered formalin. The adrenal glands, brain, epididymides, kidneys, liver, lungs, ovaries with oviducts, spleen, testes, thymus, thyroid with parathyroids and uterus were weighed from all animals at the scheduled necropsy. After routine preparation for histopathological examination, tissues were examined microscopically. In addition, liver cell proliferation in 10 mice/sex/group was assessed using immunohistochemical staining for proliferating cell nuclear antigen (PCNA).
Reproductive toxicity screening study
Rats (6 weeks of age) were randomized into groups based on body weight stratification in a block design to one of 4 groups containing a total of 10 animals/sex/group. The male and female rats were exposed individually to 0, 100, 400, or 1600 ppm TBAC for 6 h/d, 7 d/week for 70 days prior to mating, during the mating, gestation and lactation periods until the day prior to euthanasia (109-110 days for males and 108-119 days for females). Inhalation exposures of the dams were discontinued after gestation day 20 and resumed on postnatal day 5. The selected F 1 offspring were exposed to the same concentrations of their parents from (postweaning) PND 22 through 26. Clinical examinations were performed prior to and approximately 1 h following the daily inhalation exposure. During exposure, animals that were visible within the exposure chamber were observed at approximately the mid-point of the exposure period. Individual body weights and feed consumption were recorded weekly starting one week prior to study initiation and continued to study termination. Final fasted body weights were recorded prior to scheduled necropsy. Twentyone days prior to pairing, estrous cycles were determined by daily vaginal lavage and continued until evidence of mating was observed. Mating pairs were randomly selected within each exposure group and evidence of mating was confirmed by a vaginal copulatory plug or sperm positive vaginal lavage (gestation day 0). Mated females were housed in individual plastic cages with nesting material. F 0 female body weights and food consumption were determined on gestation days 0, 3, 6, 9, 12, 15, 18 and 20 and on lactation days 1, 4, 7, 14 and 21.
A necropsy was performed on male animals (after the mating period) and female animals (after selection of the F 1 generation) following isoflurane anesthesia and exsanguination and included examination of the external surface, all orifices, and the cranial, thoracic, abdominal and pelvic cavities, including viscera. Histopathology of reproductive organs was not conducted since these organs were examined in the subchronic portion of the study. Immediately upon euthanasia, F 0 sperm parameters were collected as per methods previously described (Faber et al., 2007) . Pregnancy status was determined for females that failed to deliver, and, if present, the numbers of former implantation sites were determined.
Beginning on PND 0, pups were sexed and examined for gross malformations, and the numbers of stillborn and live pups were recorded. Each pup was weighed and received a detailed physical examination on postnatal day (PND) 1, 4, 7, 14 and 21. On PND 4, litters were culled to 10 pups per litter, 5 per sex when possible. Developmental landmarks recorded for the F 1 pups included pinnal detachment, surface righting response, hair growth, incisor eruption and eye opening. One male and one female F 1 pup from each litter were exposed via inhalation exposure to the same concentration of TBAC as their parents for 6 h per day from PND 22-26. F 1 pups not selected for inhalation exposure were euthanized on PND 24 and examined internally for gross abnormalities. F 1 pups selected for TBAC exposure were euthanized on PND 27 with a complete necropsy performed.
Maternal toxicity study
Twelve-week-old nulliparous female rats were bred to resident males and randomized based on gestation day 0 body weights to one of 5 groups (22 females/group). Groups were administered TBAC at dose levels of 0, 400, 800, 1000, 1600 mg kg À1 d À1 by oral gavage from gestation day 6 to 20. Corn oil was used as the vehicle and dosing preparations were prepared daily. Detailed clinical observations were recorded (prior to dose administration during the treatment period) from gestation days 0 through 20 and observed for signs of toxicity following dose administration at approximately 0.25, 0.5, 1 and 2 hours. Individual maternal body weights and feed consumption were recorded on gestation day 0 and 6-20 (daily).
On gestation day 20, animals were euthanized, exsanguinated and a laparohysterectomy was performed. The number of corpora lutea on each ovary was recorded, the uterus was weighed and opened, and the number and location of all fetuses, early and late resorptions and the total number of implantation sites were recorded. Each viable fetus was individually sexed and weighed. Adrenal glands, brain, liver, kidneys and thymus from all dams were weighed with paired organs weighed together. All tissues were preserved in 10% neutral-buffered formalin. Organ to brain weight ratios were calculated.
Statistical analysis
In all studies, statistical analysis was conducted using twotailed tests for minimum significance levels of 1% and 5%, comparing each test substance-treated group to the control group. Parental mating, fertility, copulation and conception indices were analyzed using the Chi-square test with Yates' correction factor (Hollander and Wolfe, 1999) . Mean body weights, body weight changes and feed consumption (weekly, gestation and lactation), clinical pathology, estrous cycle lengths, pre-coital intervals, gestation lengths, implantation sites, live litter sizes, unaccounted-for sites, numbers of pups born, F 1 developmental landmark data, absolute and relative organ weights, sperm production rates, epididymal and testicular sperm numbers were analyzed for heterogeneity of variance using Levene's test (Levene, 1960) and for normality using the Shapiro-Wilk test (Royston, 1982) . Continuous FOB data, the mean maternal body weights, body weight changes, feed consumption, gravid uterine weights, organ weights and numbers of corpora lutea, implantation sites and viable fetuses from the maternal toxicity study were subjected to a parametric 1-way analysis of variance (ANOVA) to determine intergroup differences (Snedecor and Cochran, 1980) . If the ANOVA revealed statistically significant (p < 0.05) intergroup variance, Dunnett's test (Dunnett, 1964) was used to compare the test article-exposed groups to the control group. If the data were not homogeneous and normally distributed, the Kruskal-Wallis nonparametric ANOVA test (Kruskal and Wallis, 1952 ) was used to determine intergroup differences and if the ANOVA revealed statistically significant (p < 0.05) intergroup variance, Dunn's test (Dunn, 1964) was used. Motor Activity was evaluated using the SAS PROC MIXED procedure for 2-way repeated measure analysis of covariance (RANCOVA) with dose and intersession time as factors and pretest session as a covariate. Post-hoc sequential linear trend tests were conducted on each 15-min intersession time interval after it was determined that the interaction between dose and intersession time was significant. Mean fetal body weights, male, female and combined, were subjected to a parametric one-way analysis of covariance (ANCOVA) with live litter size as the covariate, to determine intergroup differences. If significant intergroup differences were detected, a Dunnett's test (Dunnett, 1964) was used to compare the test substance-treated groups to the control group.
Results
Subchronic studies
In the rat subchronic study, mean inhalation concentrations were 0, 101.1, 400.3 and 1600.3 ppm (approximately equal to 0, 135, 540 and 2160 mg/kg bw/d). There were no TBAC exposure-related effects noted during exposure observations, daily clinical observations, or in the FOB parameters measured on weeks 3 and 12. Post-hoc sequential linear trend analysis with comparison to the concurrent control group indicated lower locomotor activity in the first 15 min and higher activity in the final 15-min interval in the 1600 ppm males. Higher locomotor activity was present for the majority of the males in the 1600 ppm group, and the mean level of activity for the group was higher than the historical control range of the laboratory. The activity counts during the first 0-15 min interval were comparable to the same time interval during pretest. With analysis of activity counts from the complete 60-min session, there were no differences in total (Fig. 1a) locomotor counts for the TBAC-exposed male groups. There were no effects on total counts in the female animals for any 15-min interval or the complete 60-minute session (Fig. 1b) . The no-observed-adverse-effect-concentration (NOAEC) for subchronic effects of TBAC is 400 ppm for motor activity.
During the first week of TBAC exposure there was a treatmentrelated, transiently lower mean feed consumption (Supplementary Figure A1) and body weight gain (data not shown) only in the 1600 ppm group male and female rats and that was considered related to treatment. After the first week of exposure, feed consumption and body weight gain in TBAC treated rats was similar to control animals.
In the subchronic study on mice, mean inhalation concentrations were 0, 101, 400 and 1598 ppm (approximately equal to 0, 237, 948 and 3792 mg/kg bw/d). Evaluations during the inhalation exposure were limited by the ability to visually inspect only the animals in the closest to the window of the inhalation chamber and the inability to conduct a detailed clinical exam. Subjective findings of impaired equilibrium and labored respiration were noted during exposure primarily at the 1600 ppm level, with inconsistent findings of impaired equilibrium in two female mice at 400 ppm. There were only two observations of labored respiration during exposure at 100 ppm level, during exposure, that did not have a consistent dose response or temporal pattern indicative of a treatment-related effect. There were also scattered incidences of hyperactivity and excessive grooming that were not considered treatment-related because a similar incidence occurred in the control group or because of a lack of dose-response and temporal pattern (Supplementary Table A1a , A1b). The NOAEC for the duringexposure findings was considered to be 400 ppm based upon the transient clinical findings in the 1600 ppm group female mice and equivocal, inconsistent findings in the 400 ppm group. Acute, transient observations in mice of hyperactivity, and excessive grooming were noted during the post-exposure clinical observations and were considered to be related to TBAC exposure based on incidence, temporal pattern and appearance of a dose response relationship (Supplementary Table A1a, A1b). The majority of these findings were in the 1600 ppm group animals, with a number of the 400 ppm group animals being affected every week, although less consistently than at 1600 ppm. Occurrence of hyperactivity and excessive grooming was noted occasionally in the 100 ppm groups, but the temporal pattern was inconsistent and not considered treatment-related. Impaired equilibrium was also noted in a few animals (less than 10%) after exposure to 1600 ppm during the first two weeks of exposure. In contrast, no observations were noted in the modified FOB assessments that were performed in mice immediately post-exposure on study days 62 and 63. No TBAC-related effects were present at the daily pre-exposure observations. The NOAEC for acute, transient, post-exposure clinical signs in mice was considered to be 100 ppm based upon the occurrence of hyperactivity and excessive grooming noted in the 400 ppm group. There were no effects on body weights and feed consumption in mice exposed to TBAC (Supplementary Figures  A3a, A3b, and A4) .
In rats, TBAC inhalation exposure did not cause any gross lesions or altered hematology, clinical chemistry, and urinalysis values (Supplementary Table A2a, A2b). In the 1600 ppm groups, there was an increase in liver and/or adrenal weights (absolute and/or relative to body or brain weights; Table 3 ). There were no histopathological findings related to TBAC exposure in the liver and adrenal glands in the 1600 ppm groups (Supplementary Table A3a, A3b). The slightly higher liver and adrenal weights in male and female rats were within one standard deviation of the mean values of the historical control for the laboratory. Increased kidney weights (absolute and/or relative to body or brain weights; Table 3 ) were noted in all TBAC exposed male rats. Kidney lesions noted upon histological exam were consistent with a 2 u-globulin nephropathy and included hyaline droplet (primarily a 2 u-globulin) accumulation and basophilic tubules. While a 2 uglobulin accumulation (evident by both immunohistopathology and ELISA analysis) was consistent throughout the TBAC-exposed groups, tubular basophilia demonstrated a slightly higher incidence and severity in the 1600 ppm exposure group (Fig. 2) . Despite these alterations, kidney tubular cell proliferation indices (by PCNA assessment) were similar between TBAC-exposed and control group animals (Supplementary Table A4 ). There were no differences in TSH, total T 3 or total T 4 in TBAC-exposed rats during study weeks 4 and 13 (Table 4) . Extensive histopathological examination of lymphoid tissues did not reveal any evidence of immunotoxicity in rats exposed to TBAC in the 13-week subchronic inhalation study.
In mice, TBAC exposure-related changes were limited to increased liver weights (absolute and relative to body and/or brain weight) in the 1600 ppm male and/or female mice (Table 5 ) and a decreased circulating concentration of T 4 in male mice (at Study week 4; Table 6 ). Histological findings were limited to centrilobular hepatocellular hypertrophy in 1/10 female mice from the 1600 ppm group and a very slightly higher PCNA labeling index in the females at this exposure level. The lower mean T 4 levels in the 1600 ppm male mice group at Study week 4 were not accompanied by changes in either mean TSH or T 3 levels. There were no TBAC-related histopathological changes in the thyroid gland at week 13.
Reproductive toxicity screening study
The mean inhalation concentrations were 101, 401 and 1604 ppm for the F 0 generation and 99.8, 402.7 and 1613.1 ppm for the F 1 generation of the reproductive toxicity phase. There were no TBAC-related effects on clinical observations, survival, reproductive performance, gross or histopathology, sperm parameters (Table 7) , implantation sites, gestation length or parturition in any group (Supplementary Table A5 ). Lower mean weekly body Fig. 2 . The effect of TBAC exposure on a-2u-globulin (ng/mg of total protein) in male rats during a 13-week inhalation study. All values are the Mean ± SD of N = 10 rats.
Table 4
Hormone analysis, TSH, T 3 and T 4 , from study weeks 4 and 13 in rats exposed to TBAC and thyroid/parathyroid gland weights from study week 13 necropsy.
Control 100 ppm 400 ppm 1600 ppm
Week 4 TSH (ng/mL) Males 6.6 ± 1.1 8.5 ± 2.6 7.2 ± 2.3 8.0 ± 2.6 Females 6.0 ± 1.0 5.8 ± 0.8 6.2 ± 0.6 6.2 ± 1.4
Week 4 T 4 (uG/dL) Males 7.1 ± 0.9 7.6 ± 1.5 6.5 ± 1.0 6.5 ± 2.3 Week 13 TSH (ng/mL) Males 11.3 ± 3.03 13.0 ± 3.36 11.5 ± 2.98 13.0 ± 4.32 Females 11.7 ± 2.0 11.4 ± 2.0 10.4 ± 1.6 11.5 ± 2.3
Week 13 T 4 (uG/dL) Males 5.8 ± 1.3 5.0 ± 0.9 5.3 ± 0.8 4.6 ± 0.8 Females 3.3 ± 0.7 3.8 ± 1.0 3.5 ± 1.3 3.5 ± 0.9
Week 13 T 3 (ng/dL) Males 60.3 ± 11.2 57.5 ± 13.9 50.12 ± 9.5 52. All values are the Mean ± SD of N = 10 rats.
weights were noted from days 14 to 56 of exposure in the 1600 ppm group F 0 male group due to decreased body weight gains during the first 3 weeks of exposure (Fig. 3a) . Thereafter there were no statistically significant changes in body weights in male rats or in female rats during pre-mating, mating, gestation, or lactation (Fig. 3b) . Slightly lower mean feed consumption was observed for the 1600 ppm group males during the first 2 weeks of TBAC exposure with recovery by week 3. There were no effects on feed consumption in the remaining TBAC-exposed male or female F 0 rats (Supplementary Figure A5a , A5b, A5c, A5d).
The mean number of pups born, live litter size, percentage of males per litter at birth, postnatal survival or development were unaffected by TBAC exposure (Table 8A and B) . No effects were observed on mean body weights or rate of body weight gain in the F 1 TBAC-exposed offspring during the lactation period. A slight reduction in the rate of body weight gain was noted in the F 1 female rats from PND22-23 when exposed to 1600 ppm TBAC. All other F 1 groups had no effects on clinical signs, body weights or body weight gains and were necropsied on PND 27; there were no internal findings noted for any F 1 animals (Supplementary Table A6 ).
Maternal toxicity study
TBAC-related clinical observations (rocking, lurching or swaying while ambulating, walking on tiptoes, splayed hindlimbs, circling and/or with retropulsion) were noted in a dose-related manner in the 800, 1000 and 1600 mg kg À1 d À1 groups within the first 2 h following oral dose administration. Additional TBAC-related clinical observations noted within the first 2 h after dose administration in the 1600 mg kg À1 d À1 included hypoactivity, prostration, impaired use of right and/or left hindlimb, dragging body, and hunched posture. Lethality due to TBAC administration occurred in 1 female in the 1600 mg kg À1 d À1 group and was found dead 47 min following dose administration on gestation day 8 (underlying kidney pathology was present in this animal; see below). All other animals survived until gestation day 20. Lacrimation and salivation were noted before and after dose administration in all TBAC-treated groups throughout the treatment period (data not shown). Transient decreases in mean feed consumption values were noted in the 800, 1000 and 1600 mg kg À1 d À1 groups during GD 6-9 with concomitant decreases in mean body weight gains in those same groups during this period ( Fig. 4a and b ; mean body Table 5 Absolute and relative liver weight and PCNA counts/indices from mice exposed to TBAC for 13 weeks. All values are the Mean ± SD of N = 10 mice. a Statistically different from the control group at 0.05. Thyroid/parathyroid weights (mg) Males 6.2 ± 1.55 5.6 ± 0.92 5.5 ± 1.34 5.8 ± 0.91 Females 6.0 ± 0.86 6.2 ± 1.79 6.1 ± 1.36 6.5 ± 1.39
All values are the Mean ± SD of N = 9-10 mice. a Significantly different from the control at p < 0.05. 9.7 ± 1.0 9.8 ± 2.1 9.9 ± 3.0 10.2 ± 1.9 Motility (%) 99 ± 3.8 99 ± 4.4 99 ± 6.6 97 ± 4.6 Progressive motility (%) 76 ± 5.6 77 ± 6.8 75 ± 6.5 73 ± 5.7 Sperm morphology differential counts (%) 99.9 ± 0.4 100.0 ± 0. weight gain data not shown). Mean body weights were up to 5.6% lower in the 1600 mg kg À1 d À1 group during the entire treatment period.
Gross pathology noted in the one 1600 mg kg À1 d À1 female found dead on gestation day 8 included a small left kidney with severely distended ureters and a severely dilated renal pelvis. No TBAC-related internal findings were noted in any other animal in any dose group. Increases in absolute mean adrenal weight and in relative (to brain) mean organ weights were observed in the adrenal, liver and kidney in the 1600 mg kg À1 d À1 group (Table 9) . Decreased mean absolute and relative (to brain) thymus weights were also noted in the 1600 mg/kg bw/d group. No other TBAC-related effects on absolute organ weights were observed at 400, 800 or 1000 mg kg À1 d
À1
. Mean gravid uterine weights were not affected by TBAC administration. The mean number of viable fetuses/litter, mean fetal body weights and historical control values are presented in Table 9 . An unusually low number of live fetuses/litter within the control group litters was noted along with an increased mean fetal body weight within those litters. The mean control value of 14.4 fetuses/litter was well below the 25th quartile for the historical control database value of 14.8 fetuses/litter and well below the historical control mean of 15.2 fetuses/litter. Coincident with the decreased number of fetuses/litter in the control group, the mean fetal body weights in the control group was increased relative to the TBAC-exposed groups ( Table 9 ). The control mean fetal body weight value of 3.8 g was well above the 75th quartile for the historical control database value of 3.7 g and well above the historical control mean of 3.6 g. Similar body weight trends for each sex were evident with the control mean male and female fetal body weight values exceeding the 75th quartile for the historical control database values for each sex. The decreases in fetal body weight at the 400 and 800 mg/kg bw/d groups were not considered test-substance related due to their being equal to the historical control mean value of 3.6 g/fetus and the small difference from control group values (approximately 5%). The larger differences in mean fetal weight in the 1000 and 1600 mg/kg bw/d groups were considered test substance related and related to larger litter size and maternal toxicity. Intrauterine growth and survival, mean numbers of corpora lutea and implantation sites and the mean litter proportions of preimplantation loss were similar across all groups (Supplementary Table A7 ).
Discussion
The thirteen week repeated inhalation exposure studies reported herein demonstrates that TBAC inhalation exposure of up to 1600 ppm (7568 mg m
À3
) had minimal to no effect on body weights, feed consumption, hematology, clinical chemistry, urinalysis, and gross pathology. Acute, transient clinical signs of hyperactivity were noted in mice but not in rats. Findings of impaired equilibrium and labored respiration were noted during exposure in the 1600 ppm group with equivocal, inconsistent findings of impaired equilibrium noted at 400 ppm (1892 mg m À3 ) in two female mice during exposure. Clinical observations of hyperactivity, excessive grooming, impaired equilibrium, and excessive chewing were noted in mice during the post-exposure observations throughout the study with lower incidences in the latter part of the study. The lack of concordance between the during-exposure clinical signs observed at 400 and 1600 ppm in mice and absence of post-exposure findings may be due to differences in testing methods, or testing at different times of exposure. The NOAEC for acute, transient, post-exposure clinical signs in mice was considered to be 100 ppm based upon the occurrence of hyperactivity and excessive grooming noted in the 400 ppm group during the post-exposure observation period.
In the rat, there were no effects on the cumulative total and ambulatory activity for the entire 60-min session. There was a significant increase in motor activity counts in the last 15-min period of the locomotor activity session in the male rats exposed to 1600 ppm TBAC. The remainder of the locomotor activity pattern in this group was similar to the pre-exposure activity measures. The NOAEC for subchronic behavioral effects in rats is 400 ppm.
The subjective observation of hyperactivity immediately after exposure is not consistent with the decreased locomotor activity more commonly associated with inhalation exposure to acetates (Bowen and Balster, 1997; Christoph et al., 2003; Cruzan and Kirkpatrick, 2006) . A possible exception is a finding by Yavich et al. (1994) that an organic solvent mixture containing 31% ethyl acetate and 25% toluene increased locomotor activity, although toluene is known to increase activity (Wood and Colotla, 1990;  (a) (b) Fig. 4 . The effects of TBAC oral exposure on body weight and feed consumption in female rats from the maternal toxicity study. (a) Body weight, (b) feed consumption. All values are the Mean ± SD of N = 21-22 rats.
Table 9
The effect of TBAC oral exposure on maternal organ weights and fetal body weights in a maternal toxicity study. Bowen and Balster, 1997) . Bowen and Balster (1997) reported increased CNS excitability (jumps in air, seizures, wet-dog shakes) and impaired gait in mice that recovered within minutes of removal from the exposure chamber following exposure to amyl, ethyl and n-butyl acetate. Thus, the increased incidence of hyperactivity, impaired equilibrium and excessive grooming observed in mice in the present TBAC study could be related to CNS excitability. The rapid reversibility of acetate effects reported by Bowen and Balster (1997) could explain why effects were reported as clinical observations which were quicker to conduct on all animals compared to the FOB. Subacute inhalation to TBAC produced no clinical findings in mice (190-1500 ppm) and severe clinical findings including hypoactivity, rapid shaking of head, impaired coordination and gait in rats (1500-5066 ppm, NOEL 430 ppm) (Cruzan and Kirkpatrick, 2006) . Thus, the NOAECs for clinical findings reported in the present studies are consistent with the NOAECs reported by Cruzan and Kirkpatrick (2006) , although the types of findings were different. Increases in cumulative test session motor activity counts have also been reported in female F344 rats exposed to 5000 ppm isopropanol for 9 or 13 weeks and were reversible shortly after cessation of exposure (Burleigh-Flayer et al., 1998) .
Effects on body weight gain and feed consumption were limited to transient decreases in the 1600 ppm group male and female rats during the first week of exposure with no other body weight effects being observed in either mice or rats for the remainder of the study. Adverse effects in rats were limited to changes in the kidneys of TBAC-exposed male rats that were consistent with a 2 uglobulin nephropathy. A metabolite of TBAC, tertiary butyl alcohol (TBA) has also been reported to cause an increase in kidney tumors in F-344 male rats following chronic exposures in drinking water (Cirvello et al., 1995) and a 2 u-globulin nephropathy following inhalation exposure (Borghoff et al., 2001 ). TBA did not affect the thyroids of male and female F-344 rats when exposed chronically via drinking water (Cirvello et al., 1995) and TBAC inhalation exposures in this study did not affect circulating levels of thyroid hormones or thyroid histopathology in rats. Extensive examination of lymphoid tissues did not reveal any evidence of TBAC causing immunotoxicity in rats.
Increased liver weights were noted in male and female mice exposed to 1600 ppm TBAC for 13 weeks with limited evidence of centrilobular hepatocellular hypertrophy in female mice. The TBAC-related lower circulating T 4 levels in the male mice 1600 ppm group following 4 weeks of exposure may be related to hepatic metabolizing enzyme induction with higher turnover of T 4 since the liver is the primary site of both deiodination of T 4 to produce active T 3 and inactive reverse-T 3 and T 2 and enzymatic conjugation of T 4 to glucuronides and sulfates that are excreted (Farwell and Braverman, 1996) . The increased liver weight (without findings indicative of liver injury) observed in male and female mice exposed to 1600 ppm are consistent with the presence of metabolizing enzyme induction. A slightly higher PCNA labeling index suggests that some of the increase in liver weight in that group is also due to cell proliferation (Table 5) . TBA administered in the drinking water for 14 days has been demonstrated to induce phase I and II liver enzymes in female mice (Blanck et al., 2010) with subsequent effects on thyroid hormone homeostasis. No evidence of thyroid pathology was noted in the Blanck et al. (2010) study. No TBAC-related histopathological changes to the thyroid were present in either male or female mice in this study following 13 weeks of inhalation exposure.
The metabolism of TBAC has been reported previously (Cruzan and Kirkpatrick, 2006) . Hydrolysis of the ester bond in TBAC is one of the two major metabolic pathways, forming TBA. The ester hydrolysis pathway was favored at the 1000 ppm exposure level. Information on the toxicokinetic profile of TBAC in rats following inhalation exposures was reported by Groth and Freundt (1994) . Following inhalation exposure to either 437 or 898 ppm TBAC, blood levels of TBAC increase during a 5-h inhalation exposure with lower levels reported after cessation of the inhalation exposure. Blood levels of TBA also increase during the exposure and exceed blood TBAC levels after approximately 4 h. Following cessation of the 898 ppm inhalation exposure, the blood levels of TBAC dropped rapidly while the TBA levels decreased more slowly.
TBAC inhalation exposure did not affect any of the parameters collected in the rat reproductive toxicity screening study. Sperm parameters, reproductive performance, postnatal survival and postnatal development of the offspring were unaffected. A slight decrease in body weight gain in the F 1 female pups when directly exposed to 1600 ppm TBAC was noted following the first day of exposure. No other adverse effects were noted in weanling rats directly exposed to up to 1600 ppm TBAC. In contrast, pregnant rats receiving 800, 1000 or 1600 mg kg À1 d À1 by oral gavage bolus doses exhibited severe clinical signs of neurotoxicity and decreases in feed consumption in these same groups led to decrements in body weight gain between GD 6 and 9. Gravid uterine weights and mean number of viable fetuses/litter were unaffected; indeed the exposed groups had between 0.8 and 1.5 more pups per litter than the control group. The unusually small litter size in the control group resulted in greater mean fetal body weights when compared to the fetal body weights from the ''normal sized'' litters found in the exposed groups. These results demonstrate the maternal toxicity caused by oral administration of large amounts of TBAC with a concomitant lack of effect on fetal viability at all dose levels and fetal body weight at the 400 and 800 mg/kg bw/d dose levels. Similar adverse effects from oral administration of 1600 mg kg
À1 exposure, were reported by Yang et al. (2007) , although they did not report any adverse effects in dams receiving 800 mg kg À1 d
À1 . In addition, oral TBAC exposure had no effect on live litter size in the study by Yang and colleagues, confirming our interpretation of the litter size results observed in this study.
In conclusion, repeated inhalation exposure of P400 ppm TBAC for thirteen weeks caused clinical observations of hyperactivity in mice immediately post-exposure. These reversible clinical signs could not be confirmed when the mice were examined by a technician unaware of treatment status conducting a modified FOB. An increase in motor activity counts in male rats during the last 15-min of 1-h session following 13 weeks of exposure to 1600 ppm TBAC suggests a slight behavioral response in male rats. Repeated exposure to TBAC for 13 weeks did not affect body weight, feed consumption, and immunopathology endpoints. TBAC caused a 2 u-globulin accumulation within the male rat kidney. Increased liver and adrenal weights in rats were not accompanied by histopathological changes in those organs. Thyroid endpoints were not affected in male and female rats while male mice had decreased concentrations of T 4 at study week 4 but not week 13. There was no evidence that TBAC caused reproductive toxicity following repeated inhalation exposures throughout premating, mating, gestation and lactation. Oral gavage dose administration of TBAC to pregnant rats at dose levels of P 800 mg/kg/d caused significant signs of acute neurotoxicity and transient decreases in feed consumption and body weight gain in pregnant dams. Limited fetal evaluations indicated that exposure to maternally toxic dose levels of TBAC did not affect fetal viability.
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